Table 2.

Findings of 7 studies evaluating management strategies of postpartum OVT

ReferenceStudy designNTreatment (n)Anticoagulant durationResolution of fever, n/N (%)Recurrent VTE, n/N (%)Bleeding, n/N (%)
2  Retrospective cohort study 60 Anticoagulation alone (24) Median, 3 mo (3-6 mo) NR 0/24 (0) NR 
Antibiotics and anticoagulation (36) NR 0/36 (0) NR 
3  Prospective cohort study 13 LMWH* 3 mo NR 0/13 (0) NR 
7  Randomized controlled trial 14 Antibiotics alone (8) — 8/8 (100) (140 ± 39 h) 0/8 (0) NR 
Antibiotics and heparin (6) 0-6 d 5/5 (100) (134 ± 65 h) 0/5 (0) NR 
1  Retrospective cohort study 22 Heparin/VKA (22) 1-60 mo 0/18 (0) 0/22 (0) NR 
9  Retrospective case series 10 Antibiotics and anticoagulation (36) 10-60 d 9/10 (90) 0/36 (0) NR 
Operative intervention (adnexal excision) (1) — 1/1 (100) 0/1 (0) NR 
13  Retrospective cohort study 11 Initial antibiotics alone (11) — 0/11 (0) 1/11 (9) 0/11 (0) 
Heparin/VKA (11) 7 d to 3 mo 11/11 (100) 1/11 (9), extension of OVT 1/11 (9) 
8  Retrospective case series Initial antibiotics alone (5) — 0/5 (0) 1/6 (16.6)§ NR 
Antibiotics and heparin (4) NR 2/4 (50) 0/6 (0) NR 
Operative intervention (vein ligation and/or oophorectomy/hysterectomy) (3) — 2/3 (67) 1/6 (16.6), PE-related death intraoperatively§ NR 
11  Retrospective case series Initial antibiotics alone (4) — 0/4 (0) 0/6 (0) NR 
Antibiotics and heparin/VKA (4)|| NR 3/4 (75) 0/6 (0) NR 
Operative intervention (vein ligation/resection and/or hysterectomy) (6) — 4/6 (67) 1/6 (16.6), possible PE postoperatively NR 
ReferenceStudy designNTreatment (n)Anticoagulant durationResolution of fever, n/N (%)Recurrent VTE, n/N (%)Bleeding, n/N (%)
2  Retrospective cohort study 60 Anticoagulation alone (24) Median, 3 mo (3-6 mo) NR 0/24 (0) NR 
Antibiotics and anticoagulation (36) NR 0/36 (0) NR 
3  Prospective cohort study 13 LMWH* 3 mo NR 0/13 (0) NR 
7  Randomized controlled trial 14 Antibiotics alone (8) — 8/8 (100) (140 ± 39 h) 0/8 (0) NR 
Antibiotics and heparin (6) 0-6 d 5/5 (100) (134 ± 65 h) 0/5 (0) NR 
1  Retrospective cohort study 22 Heparin/VKA (22) 1-60 mo 0/18 (0) 0/22 (0) NR 
9  Retrospective case series 10 Antibiotics and anticoagulation (36) 10-60 d 9/10 (90) 0/36 (0) NR 
Operative intervention (adnexal excision) (1) — 1/1 (100) 0/1 (0) NR 
13  Retrospective cohort study 11 Initial antibiotics alone (11) — 0/11 (0) 1/11 (9) 0/11 (0) 
Heparin/VKA (11) 7 d to 3 mo 11/11 (100) 1/11 (9), extension of OVT 1/11 (9) 
8  Retrospective case series Initial antibiotics alone (5) — 0/5 (0) 1/6 (16.6)§ NR 
Antibiotics and heparin (4) NR 2/4 (50) 0/6 (0) NR 
Operative intervention (vein ligation and/or oophorectomy/hysterectomy) (3) — 2/3 (67) 1/6 (16.6), PE-related death intraoperatively§ NR 
11  Retrospective case series Initial antibiotics alone (4) — 0/4 (0) 0/6 (0) NR 
Antibiotics and heparin/VKA (4)|| NR 3/4 (75) 0/6 (0) NR 
Operative intervention (vein ligation/resection and/or hysterectomy) (6) — 4/6 (67) 1/6 (16.6), possible PE postoperatively NR 

VTE includes recurrent ovarian vein thrombosis, deep vein thrombosis or pulmonary embolism.

LMWH, low-molecular-weight heparin; NR: not reported; PE: pulmonary embolism; VKA: vitamin K antagonist.

*

The LMWH regimen consisted of enoxaparin 1 mg/kg subcutaneously twice daily for 2 weeks, followed by 1 mg subcutaneously daily for 3 mo.

Concomitant antibiotic use was not reported, but it was likely given in a subset of cases where fever was present.

Extension of left OVT and new right OVT despite treatment with 8 d of antibiotics and 6 d of heparin. The bleed reported was a subcutaneous hemorrhage in a different patient.

§

In combination with antibiotics alone (2 cases) or antibiotics and heparin (1 case). A patient with PE had initial antibiotics alone followed by surgery.

||

Received antibiotics and anticoagulation postoperatively after diagnostic and treatment laparotomy. One patient was treated with dicumarol postoperatively without heparin therapy.

or Create an Account

Close Modal
Close Modal